Learning Objectives: -Identify patients with newly diagnosed DLBCL for whom CD79b-targeted therapy as a component of first-line treatment would be appropriate. -Apply available clinical research findings in the formation of evidence-based approaches for the treatment of relapsed/refractory (R/R) DLBCL in patients who are unfit for intensive therapy. -Evaluate the mechanisms of action, available clinical trial findings and spectrum and frequency of toxicities associated with various CD19-directed therapies approved for R/R DLBCL. -Appraise the biological rationale for, recently presented research findings with and the potential role of CD30-targeted antibody-drug conjugate-based therapy for R/R DLBCL. -Consider published research data with and the current clinical role of bispecific antibodies targeting CD20 x CD3 in R/R DLBCL. -Counsel appropriate patients regarding the potential benefits of participation in clinical studies evaluating novel agents and strategies for DLBCL.
- Provider:Medical Learning Institute, Inc.
- Activity Link: https://www.researchtopractice.com
- Start Date: 2024-10-09 05:00:00
- End Date: 2024-10-09 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.25 hours
- MOC Credit Details: ABIM - 1.25 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: ADC Therapeutics - Amount: 14450.0 - Is Kind Support: False Source: Genentech (Any division) - Amount: 17000.0 - Is Kind Support: False Source: Genmab - Amount: 21250.0 - Is Kind Support: False Source: Incyte Corporation - Amount: 4250.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Hematology, Internal Medicine, Medical Oncology